Opinion

Video

Education and Support After Progression ALK Inhibitors

Panelists discuss how to approach patient education after progression on an ALK inhibitor, address real-world challenges during therapy transitions, and determine best options for patients progressing on lorlatinib.

Patient Education and Transition Between Therapies

Key Themes:

  • Approaches to patient education after disease progression
  • Real-world challenges during therapy transitions
  • Current options for patients progressing on lorlatinib

Notable Insights:

  • Castronovo outlined approaches to patient education when discussing next steps after progression
  • Grizzard identified real-world challenges patients face when transitioning between therapies
  • Dr Dietrich presented current best options for patients progressing on lorlatinib

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr John Mascarenhas
5 experts are featured in this series
2 experts in this video
4 experts in this video
5 experts are featured in this series
4 experts in this video
1 expert is featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo